

Brian M Alexander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9050081/publications.pdf>

Version: 2024-02-01

170
papers

9,468
citations

44069

48
h-index

45317

90
g-index

173
all docs

173
docs citations

173
times ranked

14271
citing authors

#	ARTICLE	IF	CITATIONS
1	Adult Glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2402-2409.	1.6	561
2	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
3	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. <i>Neuro-Oncology</i> , 2017, 19, 1511-1521.	1.2	483
4	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2838-2848.	7.0	403
5	Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations. <i>Cancer Discovery</i> , 2014, 4, 905-913.	9.4	395
6	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	1.2	346
7	Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. <i>JAMA Oncology</i> , 2018, 4, 1123.	7.1	238
8	Brain Metastases in Newly Diagnosed Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1069.	7.1	224
9	Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. <i>PLoS ONE</i> , 2020, 15, e0237802.	2.5	223
10	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. <i>Neuro-Oncology</i> , 2016, 18, 649-655.	1.2	221
11	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 109-117.	1.2	211
12	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	1.2	209
13	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. <i>Oncolmmunology</i> , 2015, 4, e1046028.	4.6	191
14	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. <i>Clinical Cancer Research</i> , 2018, 24, 737-743.	7.0	154
15	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	10.7	153
16	Extent of resection and overall survival for patients with atypical and malignant meningioma. <i>Cancer</i> , 2015, 121, 4376-4381.	4.1	144
17	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029.	6.3	138
18	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. <i>Cancer Discovery</i> , 2021, 11, 282-292.	9.4	132

#	ARTICLE	IF	CITATIONS
19	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 142-151.	0.8	118
20	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. <i>Journal of Clinical Oncology</i> , 2014, 32, 2025-2030.	1.6	112
21	Radiographic prediction of meningioma grade by semantic and radiomic features. <i>PLoS ONE</i> , 2017, 12, e0187908.	2.5	109
22	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	10.7	108
23	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.	30.7	105
24	Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3258-3263.	1.6	104
25	Genomic landscape of intracranial meningiomas. <i>Journal of Neurosurgery</i> , 2016, 125, 525-535.	1.6	104
26	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. <i>JCO Precision Oncology</i> , 2020, 4, 442-465.	3.0	103
27	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 3094-3105.	7.0	101
28	The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?. <i>Neuro-Oncology</i> , 2018, 20, 1034-1043.	1.2	100
29	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	1.2	99
30	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 1162-1172.	1.2	92
31	Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors. <i>JAMA Network Open</i> , 2020, 3, e2025109.	5.9	92
32	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type Glioblastomas. <i>Clinical Cancer Research</i> , 2016, 22, 1185-1196.	7.0	89
33	Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. , 2015, 3, 50.		84
34	Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2017, 19, 1688-1697.	1.2	84
35	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	1.2	83
36	Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. <i>Lung Cancer</i> , 2014, 85, 239-244.	2.0	82

#	ARTICLE	IF	CITATIONS
37	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. <i>Neuro-Oncology</i> , 2014, 16, 1547-1553.	1.2	80
38	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	7.0	79
39	Somatic mutations associated with MRI-derived volumetric features in glioblastoma. <i>Neuroradiology</i> , 2015, 57, 1227-1237.	2.2	79
40	Hazards of Hazard Ratios "Deviations from Model Assumptions in Immunotherapy. <i>New England Journal of Medicine</i> , 2018, 378, 1158-1159.	27.0	79
41	Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features. <i>Scientific Reports</i> , 2015, 5, 16822.	3.3	78
42	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. <i>Modern Pathology</i> , 2021, 34, 252-263.	5.5	78
43	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. <i>Oncotarget</i> , 2014, 5, 10596-10606.	1.8	65
44	Tumor Volume Is a Prognostic Factor in Non-Small-Cell Lung Cancer Treated With Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1381-1387.	0.8	64
45	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	1.2	64
46	Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases. <i>JAMA Oncology</i> , 2019, 5, 703.	7.1	63
47	Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. <i>Clinical Cancer Research</i> , 2019, 25, 4993-5001.	7.0	57
48	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. <i>Oncotarget</i> , 2014, 5, 8083-8092.	1.8	55
49	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. <i>Lancet Oncology</i> , 2021, 22, e456-e465.	10.7	53
50	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103.	0.6	51
51	Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications. <i>Clinical Cancer Research</i> , 2019, 25, 6339-6345.	7.0	48
52	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 384-389.	0.8	46
53	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	46
54	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. <i>Neuro-Oncology</i> , 2016, 18, 849-854.	1.2	45

#	ARTICLE	IF	CITATIONS
55	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. <i>Alzheimer's and Dementia</i> , 2020, 16, 131-143.	0.8	45
56	Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1001.	7.1	44
57	The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. <i>Acta Neuropathologica</i> , 2019, 137, 307-319.	7.7	44
58	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e33-e42.	10.7	42
59	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	1.9	41
60	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	1.2	40
61	DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 164-171.	0.8	39
62	Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. <i>Neuro-Oncology</i> , 2013, 15, 972-978.	1.2	37
63	Local control after fractionated stereotactic radiation therapy for brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 120, 339-346.	2.9	37
64	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2022, 5, e225394.	5.9	37
65	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019, 21, 1100-1117.	1.2	36
66	Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 469-474.	1.2	34
67	DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5796-5804.	7.0	32
68	Targeting DNA repair and the cell cycle in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 463-477.	2.9	32
69	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2016, 2, 16002.	5.2	31
70	Salvage stereotactic radiosurgery for breast cancer brain metastases. <i>Cancer</i> , 2012, 118, 2014-2020.	4.1	29
71	The use of external control data for predictions and futility interim analyses in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 247-256.	1.2	29
72	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	1.2	28

#	ARTICLE	IF	CITATIONS
73	Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3160-3168.	1.6	28
74	Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. <i>Modern Pathology</i> , 2020, 33, 1466-1474.	5.5	28
75	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. <i>Neuro-Oncology</i> , 2020, 22, 1339-1347.	1.2	27
76	MAPK activation and <i>HRAS</i> mutation identified in pituitary spindle cell oncocytoma. <i>Oncotarget</i> , 2016, 7, 37054-37063.	1.8	27
77	The role of whole brain radiation therapy in the management of melanoma brain metastases. <i>Radiation Oncology</i> , 2014, 9, 143.	2.7	26
78	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. <i>Lung Cancer</i> , 2020, 148, 69-78.	2.0	25
79	Importance of Extracranial Disease Status and Tumor Subtype for Patients Undergoing Radiosurgery for Breast Cancer Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e479-e486.	0.8	24
80	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A, YAP1 and VIM-KMT2A fusions. <i>Modern Pathology</i> , 2020, 33, 2307-2317.	5.5	24
81	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 908-917.	1.2	23
82	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 19.	5.2	23
83	Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. <i>Neuro-Oncology</i> , 2014, 16, 1523-1529.	1.2	22
84	Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. <i>Neuro-Oncology</i> , 2015, 17, 1106-1113.	1.2	21
85	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. <i>JCO Precision Oncology</i> , 2020, 4, 647-661.	3.0	21
86	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, 28, 728-737.	7.0	20
87	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 943-953.	3.7	19
88	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. <i>Radiotherapy and Oncology</i> , 2018, 126, 511-518.	0.6	18
89	Neurologic Complications of Radiation Therapy. <i>Neurologic Clinics</i> , 2018, 36, 599-625.	1.8	18
90	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. <i>World Neurosurgery</i> , 2019, 122, e1557-e1561.	1.3	17

#	ARTICLE	IF	CITATIONS
91	Neurologic Complications of Cranial Radiation Therapy and Strategies to Prevent or Reduce Radiation Toxicity. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 34.	4.2	17
92	Progression-free survival: too much risk, not enough reward?. <i>Neuro-Oncology</i> , 2014, 16, 615-616.	1.2	16
93	Evaluation of initial setup accuracy and intrafraction motion for spine stereotactic body radiation therapy using stereotactic body frames. <i>Practical Radiation Oncology</i> , 2016, 6, e17-e24.	2.1	16
94	To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. <i>Neuro-Oncology</i> , 2019, 21, 1239-1249.	1.2	16
95	Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. <i>Frontiers in Neurology</i> , 2020, 11, 544680.	2.4	16
96	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. <i>Modern Pathology</i> , 2020, 33, 2397-2406.	5.5	16
97	Role of isocitrate dehydrogenase in glioma. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1399-1409.	2.8	15
98	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). <i>Journal of Neuro-Oncology</i> , 2013, 111, 33-39.	2.9	15
99	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. <i>Journal of Neuro-Oncology</i> , 2017, 135, 581-591.	2.9	15
100	Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 171-179.	2.5	15
101	A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. <i>Neuro-Oncology</i> , 2020, 22, 918-927.	1.2	15
102	Enhancing radiation therapy for patients with glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 569-581.	2.4	14
103	Steroid and anticonvulsant prophylaxis for stereotactic radiosurgery: Large variation in physician recommendations. <i>Practical Radiation Oncology</i> , 2016, 6, e89-e96.	2.1	14
104	Platform trials arrive on time for glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 723-725.	1.2	14
105	Innovation Incentives and Biomarkers. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 34-36.	4.7	14
106	Urothelial cancer harbours <i>EGFR</i> and <i>HER2</i> amplifications and exon 20 insertions. <i>BJU International</i> , 2020, 125, 739-746.	2.5	14
107	Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases. <i>Journal of Neuro-Oncology</i> , 2015, 124, 429-437.	2.9	13
108	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 355-363.	2.9	13

#	ARTICLE	IF	CITATIONS
109	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <i>Translational Oncology</i> , 2021, 14, 101184.	3.7	13
110	Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. <i>Nature Communications</i> , 2022, 13, 873.	12.8	13
111	Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. <i>Journal of Neuro-Oncology</i> , 2015, 124, 137-146.	2.9	12
112	CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. <i>Modern Pathology</i> , 2021, 34, 358-370.	5.5	12
113	Characterization of Non-“Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. <i>JCO Precision Oncology</i> , 2021, 5, 1354-1376.	3.0	12
114	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	7.0	11
115	Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. <i>Pathology and Oncology Research</i> , 2021, 27, 592997.	1.9	11
116	The cost and value of glioblastoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 657-659.	2.4	10
117	Meningioma transcription factors link cell lineage with systemic metabolic cues. <i>Neuro-Oncology</i> , 2018, 20, 1331-1343.	1.2	9
118	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 1196-1206.	3.0	9
119	CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. <i>Modern Pathology</i> , 2020, 33, 2614-2625.	5.5	9
120	Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1285-1296.	3.0	8
121	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. <i>Journal of Neuro-Oncology</i> , 2016, 129, 389-393.	2.9	7
122	Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 716-724.	0.8	7
123	Hospice Utilization in Elderly Patients With Brain Metastases. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1251-1258.	6.3	7
124	Real-world association of HER2/<i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. <i>Future Oncology</i> , 2021, 17, 4101-4114.	2.4	7
125	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e1-731.e15.	1.6	7
126	<i>CDKN2C</i>-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of <i>TP53</i>/<i>RB1</i> “Wild-Type Tumor With Frequent <i>CIC</i> Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , 2020, 4, 955-971.	3.0	6

#	ARTICLE	IF	CITATIONS
127	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab017.	0.7	6
128	Optimality of testing procedures for survival data in the nonproportional hazards setting. <i>Biometrics</i> , 2021, 77, 587-598.	1.4	5
129	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2022, 27, 732-739.	3.7	5
130	Current and future directions for Phase II trials in high-grade glioma. Expert Review of Neurotherapeutics, 2013, 13, 369-387.	2.8	4
131	Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. <i>World Neurosurgery</i> , 2020, 133, e804-e812.	1.3	4
132	Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 440-443.	4.7	4
133	Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. <i>Medical Dosimetry</i> , 2021, 46, 21-28.	0.9	4
134	The effects of releasing early results from ongoing clinical trials. <i>Nature Communications</i> , 2021, 12, 801.	12.8	4
135	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e213304.	5.9	4
136	Multimodal platform for assessing drug distribution and response in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 64-77.	1.2	4
137	Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 578-578.	1.6	4
138	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	1.2	4
139	Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 765-766.	1.2	3
140	Defining optimal initial therapy for primary CNS lymphoma. <i>Lancet Haematology</i> , 2016, 3, e206-e207.	4.6	3
141	PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi204-vi205.	1.2	3
142	Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA. <i>Blood</i> , 2019, 134, 4659-4659.	1.4	3
143	Whole brain radiotherapy for non-small cell lung cancer. <i>Lancet</i> , 2017, 389, 1394-1395.	13.7	2
144	Bayesian Adaptive Randomization in Dose-Finding Trials. <i>JAMA Network Open</i> , 2018, 1, e186075.	5.9	2

#	ARTICLE	IF	CITATIONS
145	<p>Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors<p>. Lung Cancer: Targets and Therapy, 2020, Volume 11, 33-39.	2.7	2
146	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. Journal of Clinical Oncology, 2021, 39, 25-25.	1.6	2
147	Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant. Acta Medica Academica, 2021, 50, 209.	0.8	2
148	Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1023-1023.	1.6	2
149	FGFR2: A pan-genomic target.. Journal of Clinical Oncology, 2019, 37, 3099-3099.	1.6	2
150	Loss of Heterozygosity of FLT3-ITD Is Common in Acute Myeloid Leukemia and May be a More Consistent Prognostic Marker Than FLT3-ITD Allele Frequency. Blood, 2019, 134, 1437-1437.	1.4	2
151	PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas.. Journal of Clinical Oncology, 2020, 38, 757-757.	1.6	2
152	Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer. Neuro-Oncology, 2017, 19, 1015-1016.	1.2	1
153	RARE-08. GRADING CONSIDERATIONS FOR MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA. Neuro-Oncology, 2018, 20, vi237-vi238.	1.2	1
154	KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	3.0	1
155	Radiographic Prediction of Meningioma Grade and Genomic Profile. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	1
156	Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study.. Journal of Clinical Oncology, 2019, 37, 4533-4533.	1.6	1
157	Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 4585-4585.	1.6	1
158	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2003-2003.	1.6	1
159	Extra-mammary Pagetâ€™s disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 9591-9591.	1.6	1
160	DNA repair inhibition in anti-cancer therapeutics. , 0, , 936-944.		0
161	In Reply to Levra etâ€™al. International Journal of Radiation Oncology Biology Physics, 2015, 93, 218-219.	0.8	0
162	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi140-vi141.	1.2	0

#	ARTICLE	IF	CITATIONS
163	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	1.2	0
164	TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi271-vi271.	1.2	0
165	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8555-8555.	1.6	0
166	Functional profiling of a glioblastoma (GBM) patient-derived cell line (PDCL) panel to identify cell-intrinsic differential radiation response.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2069-2069.	1.6	0
167	Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature.. <i>Journal of Clinical Oncology</i> , 2019, 37, 460-460.	1.6	0
168	Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4584-4584.	1.6	0
169	Anal melanoma: A comparative comprehensive genomic profiling study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9566-9566.	1.6	0
170	PATH-16. COMPREHENSIVE GENOMIC PROFILING ACCURATELY DETERMINES 1p19q CODELETION STATUS IN GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii167-ii167.	1.2	0